Tectonic Therapeutic, Inc. (TECX): Net Income
-$74.15M
Year ended 2025-12-31
-$85.79M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$74.15M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$57.98M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$42.82M | n/m | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | -$105.89M | n/m | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | -$119.13M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$119.71M | n/m | 2022-03-17, From 2020-01-01 |
| 2019-12-31 | -$72.97M | n/m | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | -$46.36M | n/m | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | -$18.65M | n/a | 2019-03-25, From 2017-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | -$74.15M | n/m |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $168.02M | +489.4% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | -$99.96M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$119.72M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$52.49M | n/m |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | -$70.81M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$114.20M | n/m |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | -$79.20M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$146.95M | n/m |
Compare TECX, CHRS, LXEO, VYGR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗